Preventing stroke in patients with atrial fibrillation: Current treatments and new concepts

American Heart Journal

Volumn 145, Issue 3, 2003, Pages 418-423

  Connolly, Stuart J ^a,b  

^a MCMASTER UNIVERSITY   (Canada)

^b NONE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; ANTIVITAMIN K; CLOPIDOGREL; DIPYRIDAMOLE; PLACEBO; THROMBIN INHIBITOR; WARFARIN; XIMELAGATRAN;

BLEEDING; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DOSE RESPONSE; DRUG CONTRAINDICATION; DRUG EFFICACY; HEART ATRIUM FIBRILLATION; HEART LEFT ATRIUM; HIGH RISK POPULATION; HIP ARTHROPLASTY; HUMAN; LUNG EMBOLISM; PRIORITY JOURNAL; REVIEW; STROKE;

EID: 0037348936     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1067/mhj.2003.84     Document Type: Review

References (67)

1. Phillips SJ, Whisnant JP, O'Fallon WM, Frye RL. Prevalence of cardiovascular disease and diabetes mellitus in residents of Rochester Minnesota. Mayo Clin Proc 1990;65:344-59.
2. American Heart Association 1998. Heart and stroke statistical update. Dallas, Tex: American Heart Association; 1997.
3. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991;22:983-8.
4. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation: a major contributor to stroke in the elderly: the Framingham Study. Arch Intern Med 1987;147:1561-4.
5. Leckey R, Aguilar EG, Phillips SJ. Atrial fibrillation and the use of warfarin in patients admitted to an acute stroke unit. Can J Cardiol 2000;16:481-5.
6. Connolly SJ, Laupacis A, Gent M, et al. Canadian Atrial Fibrillation Anticoagulation (CAFA) Study. J Am Coll Cardiol 1991;18:349-55.
7. Petersen P, Boysen G, Godtfredsen J, et al. Placebo-controlled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: the Copenhagen AFASAK Study. Lancet 1989;1:175-9.
8. Stroke Prevention in Atrial Fibrillation Investigators. Stroke Prevention in Atrial Fibrillation Study: final results. Circulation 1991;84:527-39.
9. The Boston Area Anticoagulation Trial for Atrial Fibrillation Investigators. The effect of low-dose warfarin on the risk of stroke in patients with nonrheumatic atrial fibrillation. N Engl J Med 1990;323:1505-11.
10. Ezekowitz MD, Bridgers SL, James KE, et al. Warfarin in the prevention of stroke associated with nonrheumatic atrial fibrillation. N Engl J Med 1992;327:1406-12.
11. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in Atrial Fibrillation. Arch Intern Med 1994;154:1449-57.
12. EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993;342:1255-62.
13. Diener HC, Cunha L, Forbes C, et al. European Stroke Prevention Study 2: dipyridamole and acetylsalicylic acid in the secondary prevention of stroke. J Neurol Sci 1996;143:1-13.
14. Diener HC, Lowenthal A. Letter to the editor. J Neurol Sci 1997;153:112.
15. Posada IS, Barriates V. Alternate day dosing of aspirin in atrial fibrillation. Am Heart J 1999;138:137-43.
16. Diener HC, Lowenthal A. Antiplatelet therapy to prevent stroke: risk of brain hemorrhage and efficacy of aspirin. J Neurol Sci 1997;153:112.
17. Hart RG, Benavente O, McBride R, et al. Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta-analysis. Ann Intern Med 1999;131:492-501.
18. Hellemons BS, Langenberg M, Lodder J, et al. Primary prevention of arterial thromboembolism in patients with non-rheumatic atrial fibrillotion in general practice. Cerebrovasc Dis 1997;7(4 Suppl):11.
19. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994;343:687-91.
20. Gullov AL, Koefoed BG, Petersen P, et al. Fixed minidose warfarin and aspirin alone and in combination vs adjusted-dose warfarin for stroke prevention in atrial fibrillation: Second Copenhagen Atrial Fibrillation, Aspirin, and Anticoagulation Study. Arch Intern Med 1998;158:1513-21.
21. Morocutti C, Amabile G, Fattaposta F, et al. Indobufen versus warfarin in the secondary prevention of major vascular events in non-rheumatic atrial fibrillation. Stroke 1997;28:1015-21.
22. Taylor FC, Cohen H, Ebrahim S. Systematic review of long term anticoagulation or antiplatelet treatment in patients with non-rheumatic atrial fibrillation. BMJ 2001;322:321-6.
23. Stroke Prevention in Atrial Fibrillation Investigators. Adjusted dose warfarin versus low intensity fixed dose warfarin plus aspirin for high risk patients with atrial fibrillation: the Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;279:633-8.
24. Connolly SJ, Turpie AGG. Antithrombotic therapy in atrial fibrillation: CCS consensus conference on atrial fibrillation. Can J Cardiol 1996;12:17-20A.
25. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary. J Am Coll Cardiol 2002;38:1231-65.
26. Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001;119:194-206S.
27. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 1998;114:445-69S.
28. Hylek EM, Skates SJ, Sheehan MA, et al. An analysis of the lowest effective intensity of prophylactic anticoagulation for patients with nonrheumatic atrial fibrillation. N Engl J Med 1996;335:540-6.
29. Hylek EM, Singer DE. Risk factors for intracranial hemorrhage in outpatients taking warfarin. Ann Intern Med 1994;120:897-902.
30. Stafford RS, Singer DE. National patterns of warfarin use in atrial fibrillation. Arch Intern Med 1996;156:2537-41.
31. Schlicht JR, Davis RC, Naqi K, et al. Physician practices regarding anticoagulation and cardioversion of atrial fibrillation. Arch Intern Med 1996;156:290-4.
32. Albers GW, Yim JM, Belew KM, et al. Status of antithrombotic therapy for patients with atrial fibrillation in university hospitals. Arch Intern Med 1996;156:2311-6.
33. Brass LM, Krumholz HM, Scinto JM, et al. Warfarin use among patients with atrial fibrillation. Stroke 1997;28:2382-9.
34. Whittle J, Wickenheiser L, Venditti LN. Is warfarin underused in the treatment of elderly persons with atrial fibrillation? Arch Intern Med 1997;157:441-5.
35. Munschauer FE, Priore RL, Hens M, et al. Thromboembolism prophylaxis in chronic atrial fibrillation: practice patterns in community and tertiary-care hospitals. Stroke 1997;28:72-6.
36. The Clinical Quality Improvement Network (CQIN) Investigators. Thromboembolic prophylaxis in 3575 hospitalized patients with atrial fibrillation. Can J Cardiol 1998;14:695-702.
37. Sudlow M, Thomson R, Thwaites B, et al. Prevalence of atrial fibrillation and eligibility for anticoagulants in the community. Lancet 1998;352:1167-71.
38. Hart RG, Pearce LA, McBride R, et al. Factors associated with ischemic stroke during aspirin therapy in atrial fibrillation. Stroke 1999;30:1223-9.
39. Go AS, Hylek EM, Borowsky LH, et al. Warfarin use among ambulatory patients with non-valvular atrial fibrillation: the anticoagulation and risk factor in atrial fibrillation (ATRIA) study. Ann Intern Med 1999;131:927-34.
40. Kalra L, Perez I, Melbourn A. Risk assessment and anticoagulation for primary stroke prevention in atrial fibrillation. Stroke 1999;30:1218-22.
41. Perez I, Melbourn A, Kalra L. Use of antithrombotic measures for stroke prevention in atrial fibrillation. Heart 1999;82:570-4.
42. Bungard TJ, Ghali WA, Teo KK, et al. Why do patients with atrial fibrillation not receive warfarin? Arch Intern Med 2000;160:1295-302.
43. Hewitt A, Armstrong D. Implementing evidence based medicine in general practice: audit and qualitative study of antithrombotic treatment for atrial fibrillation. BMJ 1999;318:1324-8.
44. Gage BF, Cardinalli AB, Owens DK. The effect of stroke and stroke prophylaxis with aspirin or warfarin on quality of life. Arch Intern Med 1996;156:1829-36.
45. Antiplatelet Trialists' Collaboration. Collaborative overview of randomized trials of antiplatelet therapy: 1: prevention of death, myocardial infarction and stroke by prolonged antiplatelet therapy in various categories of patients. BMJ 1994;308:81-106.
46. Prevention of pulmonary embolism and deep vein thrombosis with low dose aspirin: Pulmonary Embolism Prevention (PEP) trial. Lancet 2000;335:1295-302.
47. Dieneer HC, Forbes C, Riekkinen PJ, et al. European Stroke Prevention Study II: efficacy and safety data. J Neurol Sci 1997;151:S27-37.
48. FitzGerald GA. Dipyridamole. N Engl J Med 1987;316:1247-57.
49. Patrono C, Coller B, Dalen JE, et al. Platelet-active drugs: the relationships among dose effectiveness, and side effects. Chest 1998;114:470-88S.
50. Leon MB, Baim DS, Popma JJ, et al. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 1998;339:1665-71.
51. Bertrand ME, Legrand V, Boland J, et al. Randomized multicenter comparison of conventional anticoagulation versus antiplatelet therapy in unplanned and elective coronary stenting: the Full Anticoagulation Versus Aspirin and Ticlopidine (FANTASTIC) Study. Circulation 1998;98:1597-603.
52. Urban P, Macaya C, Rupprecht H-J, et al. Randomized evaluation of anticoagulation versus antiplatelet therapy after coronary stent implantation in high-risk patients: the Multicenter Aspirin and Ticlopidine Trial after Intracoronary Stenting (MATIIS). Circulation 1998;98:2126-32.
53. Schomig A, Neumann F-J, Kastrati A, et al. A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents. N Engl J Med 1996;334:1084-9.
54. The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of Clopidogrel in Addition to Aspirin in Patients With Acute Coronary Syndromes without ST-Segment Elevation. N Engl J Med 2001;345:494-502.
55. Al-Saady NM, Obel OA, Camm AJ. Left atrial appendage: structure, function, and the role in thromboembolism. Heart 1999;82:547-54.
56. Manning WJ, Silverman DI, Katz SE, et al. Transesophageal echocardiography facilitated early cardioversion from atrial fibrillation using short term anticoagulation: final results of a prospective 4.5 year study. J Am Coll Cardiol 1995;25:1354-61.
57. Blackshear JL, Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation. Ann Thorac Surg 1996;61:565-9.
58. Sievert H, Lesh MD, Trepels T, et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation: early clinical experience. Circulation 2002;105:1887-9.
59. Mukilski A, Elg M, Gustafsson D. The effects of oral and intravenous direct thrombin inhibitors on the size of photochemically induced cortical infarction in rats. Thromb Res 2001;101:477-82.
60. Gustafsson D, Nystrom J, Carlsson S, et al. The direct thrombin inhibitor melagatron and its oral prodrug H 376/95: intestinal absorbtion properties, biochemical and pharmacodynamic effects. Thromb Res 2001;101:171-81.
61. Johansson L, Eriksson UG, Frison L, et al. Pharmbcodynamics and pharmacokinetics of H 376/95 after oral dosing in healthy male subjects of different ethic origin. Blood 2000;96:56A.
62. Johansson L, Eriksson UG, Frison L, et al. Pharmacokinetics of H 376/95 in young and healthy subjects. Blood 2000;96:57A.
63. Eriksson UG, Gustafsson D, Mandema J, et al. Pharmacokinetics of melagatron, the active form of the oral, direct thrombin inhibitor H 376/95, in orthopaedic surgery patients treated to prevent deep vein thrombosis and pulmonary embolism. Blood 2000;96:93B.
64. Elg M, Gustafsson D, Carlsson S. Antithrombotic effects and bleeding tlme of thrombin inhibitors and warfarin in the rat. Thromb Res 1999;94:187-97.
65. Mattsson C, Menschik-Lundin A. Prothrombin time assays are unsuitable for monitoring the effects of melagatron, the active form of the oral, direct thrombin inhibitor H 376/95. Blood 2000;96:98B.
66. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor h 376/95 with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase II dose-finding study. Blood 1996;101:491A.
67. Petersen P. First experience with the oral direct thrombin inhibitor H 376/95 compared to warfarin in patients with non-valvular atrial fibrillation (NVAF). J Gen Intern Med 2001;16(1 Suppl):164.